Matthew Kapusta Sells 41,671 Shares of uniQure (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) CEO Matthew Kapusta sold 41,671 shares of the company’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $50.00, for a total value of $2,083,550.00. Following the transaction, the chief executive officer directly owned 521,795 shares in the company, valued at $26,089,750. This represents a 7.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

uniQure Price Performance

QURE stock opened at $46.29 on Monday. The firm has a 50 day moving average of $24.74 and a 200 day moving average of $22.17. The stock has a market capitalization of $2.92 billion, a PE ratio of -13.30 and a beta of 0.98. uniQure N.V. has a 52 week low of $8.73 and a 52 week high of $71.50. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The firm had revenue of $3.56 million for the quarter, compared to analyst estimates of $5.21 million. Sell-side analysts forecast that uniQure N.V. will post -3.64 earnings per share for the current year.

Institutional Trading of uniQure

Several hedge funds have recently modified their holdings of the stock. Jones Financial Companies Lllp grew its position in uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 509 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of uniQure by 5.5% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock worth $243,000 after acquiring an additional 533 shares in the last quarter. Arizona State Retirement System grew its holdings in uniQure by 6.0% in the fourth quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock valued at $267,000 after purchasing an additional 627 shares during the last quarter. Ensign Peak Advisors Inc lifted its holdings in shares of uniQure by 21.7% in the fourth quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock valued at $87,000 after purchasing an additional 650 shares in the last quarter. Finally, FNY Investment Advisers LLC increased its position in uniQure by 76.7% during the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock worth $96,000 after buying an additional 718 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts recently weighed in on QURE shares. Chardan Capital lifted their price target on uniQure from $31.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Mizuho upgraded uniQure from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $12.00 to $35.00 in a research note on Wednesday, March 11th. Cantor Fitzgerald upgraded shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 target price for the company in a research report on Wednesday, June 17th. Wall Street Zen raised uniQure from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Finally, Sanford C. Bernstein downgraded shares of uniQure to a “market perform” rating in a report on Tuesday, March 3rd. Twelve investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, uniQure presently has a consensus rating of “Moderate Buy” and an average target price of $58.92.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.